Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824, TriAd Vaccine, and N-803 in Resectable HNSCC
NCT04247282Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Jun 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04247282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247282.